D. Duda

Molecular Biology · 2004–2021

A researcher in the Science corpus: 11 papers; trusts 4 researchers and is trusted by 3 researchers here, as inferred from the citation graph.

Subfields

• Molecular Biology — 185 citations into it; #7,823 of 17,773 by trust here, #2,498 by citations
• Oncology — 115 citations into it; #882 of 1,698 by trust here, #371 by citations
• Cancer Research — 99 citations into it; #1,116 of 1,780 by trust here, #549 by citations
• Immunology — 49 citations into it; #1,785 of 2,160 by trust here, #1,389 by citations
• Immunology and Allergy — 14 citations into it
• Biotechnology — 12 citations into it

Whom D. Duda trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. Rakesh K. Jain
2. Peter Carmeliet
3. N. Ferrara
4. D. Pardoll

Who trusts D. Duda overall

1. Rakesh K. Jain
2. Peter Carmeliet
3. Dai Fukumura
4. J. Joyce

Papers from D. Duda's perspective

Ordered by how strongly the researchers D. Duda trusts endorse each paper. Same corpus, a different order for every researcher.

1. Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy (Nature Medicine)
2. Dissecting tumour pathophysiology using intravital microscopy (Nature Reviews. Cancer)
3. Pathology: Cancer cells compress intratumour vessels (Nature)
4. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. (Cancer Research)
5. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. (New England Journal of Medicine)
6. Angiogenesis in life, disease and medicine (Nature)
7. Tumor Response to Radiotherapy Regulated by Endothelial Cell Apoptosis (Science)
8. Pathophysiological consequences of VEGF-induced vascular permeability (Nature)
9. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? (Nature Reviews. Cancer)
10. The blockade of immune checkpoints in cancer immunotherapy (Nature Reviews. Cancer)

Their papers

• Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer (2004) — 2,071 citations
• AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. (2007) — 1,814 citations
• Lessons from phase III clinical trials on anti-VEGF therapy for cancer (2006) — 1,099 citations
• NORMALIZATION OF THE VASCULATURE FOR TREATMENT OF CANCER AND OTHER DISEASES (2011) — 1,574 citations
• Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy (2012) — 1,011 citations
• Vascular normalization as an emerging strategy to enhance cancer immunotherapy (2013) — 595 citations
• Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) — 1,744 citations
• Angiogenesis in brain tumours (2007) — 1,441 citations
• NASH limits anti-tumour surveillance in immunotherapy-treated HCC (2021) — 1,066 citations
• Engineering vascularized tissue (2005) — 810 citations
• Differentiating the pathologies of cerebral malaria by postmortem parasite counts (2004) — 685 citations